The Long Game

Sandy & Ross

The Long Game is a podcast that demystifies the science shaping our lives, and explores how great ideas built in Scotland become real-world medicines, devices, and companies at the cutting edge of life sciences.

  1. Jul 31

    E19: The Bio-Founder's Playbook, Part 2b: How to Raise Funding in Scotland

    Unlock the secrets to launching a biotech startup from Scotland’s leading experts; avoid common pitfalls, tap into critical funding sources, and learn when and how to scale beyond borders. Most founders rush into company formation without the right foundation. Prof Ross Cagan, Director of the McNabb Center, and Dr Sandy Weir, Tech Innovation Leader, expose the biggest mistakes biotech entrepreneurs make when transitioning from research to business. They reveal how to use university resources to de-risk your project, the true role of non-dilutive funding, and the importance of timing in fundraising. Discover why early company formation can hamper your growth and learn the smart steps to validate your idea, protect your IP, and build a credible team before pitching to investors. In this episode, Ross and Sandy continue to share real-world insights from their vast experience, highlighting the difference between innovative science and investable companies. They caution against rushing early, over-diluting, or pitching without thorough market and regulatory understanding. Plus, they offer practical tips for securing any startup milestone, backing Scotland’s vibrant biotech ecosystem, and building a truly global company. Perfect for early-stage founders, biotech entrepreneurs, and researchers eager to turn their innovative ideas into impactful businesses. If you're ready to navigate the complex funding landscape and avoid costly pitfalls, this episode is your ultimate guide to raising capital, scaling smartly, and making a real difference in healthcare.

About

The Long Game is a podcast that demystifies the science shaping our lives, and explores how great ideas built in Scotland become real-world medicines, devices, and companies at the cutting edge of life sciences.